Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + Nilotinib in CML
NCT02973711Phase 2Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jan 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in chronic myeloid leukemia (CML), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Maximum Tolerated Dose at 2 years and Complete Molecular Response at 2 years. Planned start Jan 2018; status: withdrawn.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02973711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973711.